Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


User Fees Collection Better Than Expected; Reserve Fund Could Lower FY '12 Fees

This article was originally published in The Pink Sheet Daily

Executive Summary

Manufacturer user fees paid for about 60% of FDA's drug review costs in fiscal year 2009.

You may also be interested in...

FDA Expects Sharp Drop In Drug Applications This Year

Announcing the PDUFA fees for fiscal 2011, agency says it expects to receive 117.5 fee-paying full application equivalents in the current fiscal year, down 16 percent from the 2009 level.

FDA Receives Assurances That PDUFA Remains Priority on Capitol Hill

As Congress prepared to adjourn for summer recess without reauthorizing the Prescription Drug User Fee Act, FDA Commissioner Andrew von Eschenbach sent an e-mail to agency employees Aug. 3 designed to lessen worries about job security

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts